Cargando…

Pirfenidone inhibits cell fibrosis in connective tissue disease-associated interstitial lung disease by targeting the TNF-α/STAT3/KL6 pathway

BACKGROUND: To explore the effect and mechanism of pirfenidone in inhibiting pulmonary fibrosis in connective tissue disease-associated interstitial lung disease (CTD-ILD). METHODS: From 2018 to 2020, 50 CTD-ILD patients were enrolled in the clinical study. Based on whether pirfenidone was used duri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuo, Yanhua, Liu, Jing, Xu, Huaheng, Li, Yanxia, Tao, Ran, Zhang, Zongfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264050/ https://www.ncbi.nlm.nih.gov/pubmed/35813760 http://dx.doi.org/10.21037/jtd-22-41

Ejemplares similares

Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease
por: Lee, Jeong Seok, et al.
Publicado: (2019)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Expression of S100A9 and KL-6 in common interstitial lung diseases
por: Lin, Li, et al.
Publicado: (2022)

The Diagnostic Value of the Interstitial Biomarkers KL-6 and SP-D for the Degree of Fibrosis in Combined Pulmonary Fibrosis and Emphysema
por: Chiba, Shigeki, et al.
Publicado: (2012)

Prognostic role of blood KL-6 in rheumatoid arthritis–associated interstitial lung disease
por: Kim, Ho Cheol, et al.
Publicado: (2020)

The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study
por: Wang, Jiaqi, et al.
Publicado: (2022)

Effects of pirfenidone on renal function in patients with interstitial pneumonia
por: Matsumoto, Jun, et al.
Publicado: (2021)

Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
por: Li, Ting, et al.
Publicado: (2016)

Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease
por: Mandovra, Neha P., et al.
Publicado: (2023)

Blood KL-6 predicts prognosis in primary Sjögren’s syndrome-associated interstitial lung disease
por: Kim, Yun Jae, et al.
Publicado: (2022)

Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
por: Jehn, Lutz B., et al.
Publicado: (2023)

Correlation between CT Score and KL-6: A Severity Assessing in Juvenile Dermatomyositis Associated Interstitial Lung Disease
por: Wang, Chi, et al.
Publicado: (2023)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Role of pirfenidone in the management of pulmonary fibrosis
por: Meyer, Keith C, et al.
Publicado: (2017)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease
por: Kim, Kyuhwan, et al.
Publicado: (2023)

Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
por: Cassone, Giulia, et al.
Publicado: (2020)

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
por: Spagnolo, Paolo, et al.
Publicado: (2021)

Connective tissue disease-related interstitial lung disease is alleviated by tripterine through inhibition of the PI3K/Akt, apoptosis, and TNF-α signalling pathways
por: Zhu, Wen, et al.
Publicado: (2022)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Serum KL‐6 level is a prognostic marker in patients with anti‐MDA5 antibody‐positive dermatomyositis associated with interstitial lung disease
por: Ye, Yan, et al.
Publicado: (2019)

Evaluation of the Clinical Value of KL-6 and Tumor Markers in Primary Sjögren’s Syndrome Complicated with Interstitial Lung Disease
por: Wei, Fengqin, et al.
Publicado: (2023)

Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer
por: Park, Hwa Kyung, et al.
Publicado: (2023)

Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients
por: Huang, Hui, et al.
Publicado: (2015)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Comparison of Characteristics of Connective Tissue Disease-Associated Interstitial Lung Diseases, Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Diseases, and Idiopathic Pulmonary Fibrosis in Chinese Han Population: A Retrospective Study
por: Pan, Lin, et al.
Publicado: (2013)

Activation of Myofibroblast TRPA1 by Steroids and Pirfenidone Ameliorates Fibrosis in Experimental Crohn's Disease
por: Kurahara, Lin Hai, et al.
Publicado: (2017)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?
por: Latella, Giovanni, et al.
Publicado: (2020)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Digital Clubbing Is Associated with Higher Serum KL-6 Levels and Lower Pulmonary Function in Patients with Interstitial Lung Disease
por: Shiraishi, Kazushige, et al.
Publicado: (2018)

Comparison of Clinical Features between the High and Low Serum KL-6 Patients with Acute Exacerbation of Interstitial Lung Diseases
por: Tagami, Yoichi, et al.
Publicado: (2021)

Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE
por: Deng, Linxia, et al.
Publicado: (2021)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
por: Cabrera Cesar, Eva, et al.
Publicado: (2021)

Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: A cohort study
por: Chiu, Yu-Hsiang, et al.
Publicado: (2023)

A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article
por: Huang, Hui, et al.
Publicado: (2016)

Combination of Niclosamide and Pirfenidone Alleviates Pulmonary Fibrosis by Inhibiting Oxidative Stress and MAPK/Nf-κB and STATs Regulated Genes
por: Wanas, Hanaa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ja8k5u3skq2mskhsffc0k40upg